Drug Target Review Synthetic Biology ebook 2022
Supported by:
Published: 21 September 2022
Share this post
- Like
- Digg
- Del
- Tumblr
- VKontakte
- Buffer
- Love This
- Odnoklassniki
- Meneame
- Blogger
- Amazon
- Yahoo Mail
- Gmail
- AOL
- Newsvine
- HackerNews
- Evernote
- MySpace
- Mail.ru
- Viadeo
- Line
- Comments
- Yummly
- SMS
- Viber
- Telegram
- Subscribe
- Skype
- Facebook Messenger
- Kakao
- LiveJournal
- Yammer
- Edgar
- Fintel
- Mix
- Instapaper
- Copy Link
Within this ebook are features on synthetic biology, covering synthetic biotics and their potential to treat a wide range of diseases and conditions, while another piece examines the therapeutic directions the synthetic biology field will likely take in the future.
Researchers are clearing the path for a new class of medicine – biotherapeutics called synthetic biotics, which are created by programming or engineering bacteria to metabolise or secrete well-validated targets of disease pathophysiology. In the first article, Dr Caroline Kurtz, Synlogic, discusses how synthetic biotics work and their potential applications in the treatment of a broad range of conditions including rare diseases, metabolic conditions, autoimmune diseases and inflammatory diseases.
In the second article, Dr Dan Mandell, Co-Founder and CEO of GRO Biosciences, explains how synthetic biology has served as a proving ground for integrating forward engineering principles into living cells, but is now reshaping our understanding of the limits of cell- and molecular-based medicines.
In this ebook:
- Advancing novel biotherapeutics based on synthetic biology
Dr Caroline Kurtz, Chief Development Officer at Synlogic - Synthetic biology is ready for the therapeutic limelight
Dr Dan Mandell, Co-Founder and CEO at GRO Biosciences